Literature DB >> 12700030

The insulin-like growth factor/insulin system in epithelial ovarian cancer.

Kimberly R Kalli1, Cheryl A Conover.   

Abstract

Ovarian cancer is the most lethal of the gynecologic malignancies, in part because the lack of striking symptoms in many women often results in diagnosis only after the disease has spread. In order to develop rational biologic or pharmacologic therapies, it is important to understand the biology of both normal and malignant ovarian epithelial cells. This review will summarize current knowledge of the expression and function of proteins in the insulin-like growth factor system in ovarian epithelium, including the peptide ligands, receptors, binding proteins, and binding protein proteases. All components of this complex regulatory system are present in the ovarian epithelium and may play important roles in regulating the normal biology of ovarian surface epithelial cells or the transformed phenotype of ovarian carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700030     DOI: 10.2741/1034

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  10 in total

Review 1.  Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis.

Authors:  Christina M Nagle; Catherine M Olsen; Torukiri I Ibiebele; Amanda B Spurdle; Penelope M Webb
Journal:  Eur J Nutr       Date:  2012-05-22       Impact factor: 5.614

2.  A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.

Authors:  Marc A Becker; Paul Haluska; Laurie K Bale; Claus Oxvig; Cheryl A Conover
Journal:  Mol Cancer Ther       Date:  2015-02-18       Impact factor: 6.261

Review 3.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

4.  The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions.

Authors:  Brittany Lees; Charles A Leath
Journal:  Curr Obstet Gynecol Rep       Date:  2015-09-23

5.  Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells.

Authors:  Zongxian Cao; Ling-Zhi Liu; Dan A Dixon; Jenny Z Zheng; Bala Chandran; Bing-Hua Jiang
Journal:  Cell Signal       Date:  2007-02-08       Impact factor: 4.315

Review 6.  Platinum resistance in breast and ovarian cancer cell lines.

Authors:  Niels Eckstein
Journal:  J Exp Clin Cancer Res       Date:  2011-10-04

7.  Glycemic Index, Glycemic Load, and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cohort.

Authors:  Jennifer M Mongiovi; Jo L Freudenheim; Kirsten B Moysich; Susan E McCann
Journal:  J Nutr       Date:  2021-06-01       Impact factor: 4.798

8.  The insulin and igf-I pathway in endocrine glands carcinogenesis.

Authors:  Roberta Malaguarnera; Alaide Morcavallo; Antonino Belfiore
Journal:  J Oncol       Date:  2012-08-08       Impact factor: 4.375

9.  Antisense oligonucleotide suppression of human IGF-1R inhibits the growth and survival of in vitro cultured epithelial ovarian cancer cells.

Authors:  Jie Tang; Junjun Li; Guqing Zeng; Yanxiang Tang; Wenfang Tian; Jie He; J Philippe York; Xuefeng Xia
Journal:  J Ovarian Res       Date:  2013-10-08       Impact factor: 4.234

10.  Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.

Authors:  Diogo Torres; Xiaonan Hou; Laurie Bale; Ethan P Heinzen; Matthew J Maurer; Valentina Zanfagnin; Ann L Oberg; Cheryl Conover; S John Weroha
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.